Latest filing published 19 Mar 2026 for Maxcyte, INC., €7,188. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Filings by Douglas J. Swirsky span 2 companies, the busiest being Maxcyte, Inc. and Cellectar Biosciences, Inc. In total, 6 filings cover trades dated from 14 September 2021 to 17 March 2026.
The open-market side counts 2 purchases for €77k alongside 2 sales for €27k. Purchases outweigh sales by €50k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 2 share grants. 2026 to date brings no purchases and 1 sale.
The latest filing, published on 19 March 2026, reports an open-market sale of €7,188 in Maxcyte, Inc. The most recent open-market purchase was published on 13 August 2025, 431 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations